Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-06
2007-02-06
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S300000, C530S350000, C435S440000, C435S069100
Reexamination Certificate
active
10815562
ABSTRACT:
The disclosure provides a novel class of cationic cathelin-like peptides and polypeptides that have antimicrobial activity. These peptides are useful for inhibiting microbial infection or growth.
REFERENCES:
patent: 4482680 (1984-11-01), Sheldon
patent: 5618675 (1997-04-01), Larrick
patent: 6040291 (2000-03-01), Hirata
patent: 2003/0022829 (2003-01-01), Maury
patent: 1 358 888 (2003-11-01), None
patent: WO96/08508 (1996-03-01), None
patent: WO 02/13857 (2002-02-01), None
patent: WO 02/060468 (2002-08-01), None
Boman et al. “Prepro-FALL-99” Jun. 6, 1996, Database: A—Geneseq—21, Accession No. AAR92924, alignment result 4.
Benincasa et al., “In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs,” Peptides, vol. 24, No. 11, pp. 1723-1731, Nov. 2003.
Gallo et al., “Identification of CRAMP, a cathelin-related antimicriobial peptide expressed in the embryonic and adult mouse,” J. Biol. Chem., vol. 272, No. 20, pp. 13088-13093, May 16, 1997.
Gennaro et al., “Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action,” Curr. Pharm. Des. vol. 8, No. 9, pp. 763-778, 2002.
Gennaro et al., “Structural features and biological activities of the cathelicidin-derived antimicrobial peptides,” Biopolymers, vol. 55, No. 1, pp. 31-49, 2000..
Gennaro et al. “Biological characterization of a novel mammalian antimicrobial peptide,” Biochim Biophys Acta, vol. 1425, No. 2, pp. 361-368, Oct. 23, 1998.
Ha et al., “Synthesis and Antibioteic Activities of CRAMP, a Cathelin-related Antimicrobial Peptide and Its Fragments,” Bull. Korean Chem. Soc., vol. 20, No. 9, pp. 1073-1077, 1999.
Howell et al., “Selective Killing of Vaccinia Virus by LL-37: Implications for Eczema Vaccinatum,” J. of Immunol., vol. 172, pp. 1763-1767, 2004.
Ong et al., “Endogenous Antimicrobial Peptides And Skin Infections In Atopic Dermatitis,” N Engl. J. Med., vol. 347, No. 15, pp. 1151-1160, Oct. 10, 2002.
Sanchez et al., “Overexpression and structural study of the cathelicidin motif of the protegrin-3 precursor,” Biochemistry, vol. 41, No. 1, pp. 21-30, Jan. 8, 2002.
Skerlavaj et al., “Structural and functional analysis of horse cathelicidin peptides,” Antimicrob. Agents Chemother., vol. 45, No. 3, pp. 715-722, Mar. 2001.
Tjabringa et al., “The Antimicrobial Peptide LL-37 Activates Innate Immunity at the Airway Epithelial Surface by Transactivation of the Epidermal Growth Factor Receptor,” J. or Immunol., vol. 171, pp. 6690-6696, 2003.
Zaiou et al., “Antimicrobial and Protease Inhibitory Functions of the Human Cathelicidin (hCAP18/LL-37) Prosequence,” J. of Invest. Derm., vol. 120, No. 5, pp. 810-816, May 2003.
Zanetti et al., “Cathelicidin peptides as candidates for a novel class of antimicrobials,” Curr. Pharm. Des., vol. 8, No. 9, pp. 779-793, 2002.
Zanetti et al., “Structure and biology of cathelicidins,” Adv. Exp. Med. Biol., vol. 479, pp. 203-218, 2000.
Zanetti et al., “The cathelicidin family of antimicrobial peptide precursors: a component of the oxygen-independent defense mechanisms of neutrophils,” Ann. N. Y. Acad. Sci., vol. 832, pp. 147-162, Dec. 15, 1997.
Zanetti, Margherita; Renato Gennaro, Barbara Skerlavaj; Linda Tomasinsig and Raffaella Circo; “Cathelicidin Peptides as Candidates for a Novel Class of Antimicrobials” Current Pharaceutical Design, 2002, vol. 8, No. 9, pp. 779-793.
Smeianov, Vladimir; Kellie Scott, and Gregor Reid; “Activity of Cecropin P1 and FA-LL-37 Against Urogenital Microflora” Microbes and Infections, 2000, vol. 2, pp. 773-777.
Johansson, Jan; Gudmundur H. Gudmundsson; Martin E. Rottenberg; Kurt D. Berndt; and Birgitta Agerberth; “Conformation-dependent Antibacterial Activity of the Naturally Occurring Human Peptide LL-37” The Journal of Biological Chemistry; vol. 273, No. 6, Feb. 6, 1998, pp. 3718-3724.
Gallo Richard L.
Nizet Victor
Zaiou Mohamed
Buchanan Ingersoll & Rooney LLP
Mitra Rita
The Regents of the University of California
The United States of America as represented by the Department of
Weber Jon
LandOfFree
Therapy for microbial infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy for microbial infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for microbial infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855675